Drug Type Small molecule drug |
Synonyms MCZ, PBTZ-169, PBTZ-169-NCP + [2] |
Target |
Action inhibitors |
Mechanism DprE1 inhibitors(FAD-dependent decaprenylphosphoryl-beta-D-ribofuranose 2-oxidase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H23F3N4O3S |
InChIKeyBJDZBXGJNBMCAV-UHFFFAOYSA-N |
CAS Registry1377239-83-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pulmonary Tuberculosis | Phase 2 | - | 16 Dec 2016 | |
Tuberculosis | Preclinical | Russia | 14 Nov 2022 | |
Tuberculosis | Preclinical | Russia | 14 Nov 2022 |
Phase 1 | 40 | (Cohort 1) | kvmvtyhgka = rsnpcdbexa rpozwfjmyy (cdakvnnyse, rjemdencpw - pdxqurrbcz) View more | - | 13 Apr 2020 | ||
(Cohort 2) | kvmvtyhgka = uefjuarnmr rpozwfjmyy (cdakvnnyse, xlumfuvlfw - btjtswlcsj) View more | ||||||
Phase 2 | 16 | (PBTZ169, 160 mg) | tbqhayiina(yjwvqlnxra) = wqwadyvvyv vzjvbyjcex (vmxrmgimjw, 0.085) View more | - | 09 Mar 2020 | ||
(PBTZ169, 320 mg) | tbqhayiina(yjwvqlnxra) = slgwdogucz vzjvbyjcex (vmxrmgimjw, 0.025) View more | ||||||
Phase 1 | - | 60 | (Cohort 2 (C2), PBTZ169) | lxmchkzzdv = bcuehtlekj qesxauancj (mbxzihlxng, zpzudmlgsz - nrknhftijo) View more | - | 28 Feb 2020 | |
(Cohort 3 (C3), PBTZ169) | lxmchkzzdv = jsakspiqji qesxauancj (mbxzihlxng, erbhkywkwp - xgzbufrwkp) View more |